Expression Level of Hepatoma-Derived Growth Factor Correlates with Tumor Recurrence of Esophageal Carcinoma
- 2 May 2007
- journal article
- Published by Springer Science and Business Media LLC in Annals of Surgical Oncology
- Vol. 14 (7), 2141-2149
- https://doi.org/10.1245/s10434-007-9369-9
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Hepatoma-Derived Growth Factor Is a Novel Prognostic Factor for Hepatocellular CarcinomaAnnals of Surgical Oncology, 2006
- Expression Level of Valosin-Containing Protein (p97) Is Associated with Prognosis of Esophageal CarcinomaClinical Cancer Research, 2004
- Expression of hepatoma‐derived growth factor in hepatocellular carcinomaCancer, 2003
- Hepatoma-derived growth factor is highly expressed in developing liver and promotes fetal hepatocyte proliferationHepatology, 2002
- Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trialThe Lancet, 2002
- Cancer Statistics, 2001CA: A Cancer Journal for Clinicians, 2001
- Hepatoma-derived growth factor stimulates smooth muscle cell growth and is expressed in vascular developmentJCI Insight, 2000
- Survival of patients with oesophageal and gastric cancers in EuropeEuropean Journal Of Cancer, 1998
- An endothelial growth factor involved in rat renal development.JCI Insight, 1998
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958